Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial

CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562

Source: Clinical Breast Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research